DDInter1969 DDInter1376
Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan. Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment. Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Zolmitriptan {u} (Compound) resembles {v} (Compound) Almotriptan
Zolmitriptan {u} (Compound) resembles {v} (Compound) Eletriptan
Zolmitriptan {u} (Compound) binds {v} (Gene) HTR1D
Zolmitriptan {u} (Compound) palliates {v} (Disease) migraine
Zolmitriptan {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 1d Receptor Agonists
Zolmitriptan {u} (Compound) downregulates {v} (Gene) RPS4Y1
Zolmitriptan {u} (Compound) causes {v} (Side Effect) Muscle tightness
Zolmitriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Zolmitriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Zolmitriptan {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Zolmitriptan (Compound) resembles Almotriptan (Compound)
Zolmitriptan (Compound) resembles Eletriptan (Compound)
Zolmitriptan (Compound) binds HTR1D (Gene)
Zolmitriptan (Compound) palliates migraine (Disease)
Zolmitriptan (Compound) is included by Serotonin 1d Receptor Agonists (Pharmacologic Class)
Zolmitriptan (Compound) downregulates RPS4Y1 (Gene)
Zolmitriptan (Compound) causes Muscle tightness (Side Effect)
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Zolmitriptan may lead to a major life threatening interaction when taken with Dexfenfluramine